Skip to main content

Table 3 Comparison of outcomes of contemporary SBRT

From: Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer

Author (Year) N Pt type Dose FU (yr) Toxicity Outcome Ref
King (2009) 67 Low-risk; PSA < 10, G < = 3 + 4; <= T2a/b 7.25 x 5 2.7 GU: Grade 4 (0 %) 3 (3 %), 2 (5 %), and 1 (23 %) respectively.
Rectal Grade 3 (0 %), 2 (2 %), and 1 (12.5 %).
(5 years) 94 % relapse free survival [24]
Boike (2011) 45 PSA ≤ 20, G ≤ 7, ≤T2b 9-10 x 5 2.5 GI: 3 (2 %), 2 (16 %); GU: 3 (4 %); 2 (27 %)   [48]
Chen (2013) 100 Low/intermediate risk (8 high) 7-7.25 x 5 2.3 GU ≥2 (31 %); GI ≥ 2 (1 %) (2 years) 99 % (31 % bounce, 21 % late transient urinary symptom flare) [21]
Katz (2010) 73 Intermediate/High Risk 6-7 x 3 (Boost) 2.75 2 (7 %) (3 years) 89.5 % (Intermediate); 77.7 % (high) [39]
Suy (2010) 24   6.5 x 3 (Boost) 0.8 GU 2 (13 %); GI 2 (4 %)   [49]
Katz (2010) 304 Low/intermediate/high 7-7.25 x 5 2.5 Acute
GU 2 (4.7 %); GI 2 (4 %);
Late
GU 3 (0.5 %); 2 (6 %)
GI 2 (3 %)
4 failures (16 % bounce) [50]
Jabarri (2012) 38 Low/intermediate/high 9.5 x 4 (mono); 9.5 x 2 (boost) 1 Acute
GU 2 (42 %); GI 2 (11 %)
Late
G3 3 (5 %)
No failures [25]
King (2013) 1100 (pooled) Low (58 %), intermediate (30 %) and high-risk (11 %). 36.25 Gy in 4–5 fx 3   (5 years) 93 % (16 % bounce) [19]